Lv62
1880 积分 2023-02-22 加入
中国多发性骨髓瘤诊治指南（2020年修订）
8天前
已完结
急性肾损伤的研究进展
9天前
已完结
2019年新型抗肿瘤药物相关肾脏损伤研究进展
9天前
已关闭
Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study
10天前
已完结
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
21天前
已完结
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
24天前
已完结
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
1个月前
已完结
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
1个月前
已完结
Acute renal failure secondary to imatinib mesylate treatment in prostate cancer
1个月前
已完结
皖公网安备34019202002308
